2025-03-22
Preclinical studies have shown that the anti-tumor activity of CS2009 is superior to that of potential competitors. In addition, CS2009 is expected to further improve the efficacy of PD-L1-low expression or PD-L1-negative patients who have not responded well to PD-(L)1 therapy by targeting PD-1 and VEGFA by combining CTLA-4 inhibition, and has the potential to become a first-in-class/best-in-class next-generation tumor immunoskeleton product to replace existing PD-(L)1-based therapies.